Arsenic and arsenic species in MOD, POD, and disposable POD electronic cigarette aerosols: a pilot study

Sample preparation methods for elemental analysis in electronic cigarette aerosols: a critical review

In the last decade, e-cigarettes have been marketed as a less harmful alternative to classical tobacco smoking and are currently being used by millions of people. An e-cigarette consists of an e-liquid and a heating device, generating an aerosol that the user can inhale. Recently, several studies have shown that metals and metalloids, including As, Cd, and Pb, known carcinogens, were present in these aerosols. To ensure the accuracy of dose-toxicity estimations, it is essential to have access to reliable and reproducible methods for estimating the dose in question. Although more standardization methodologies were introduced in the analysis of metal(loid)s from aerosols, a huge divergence in sample preparation can be found in the literature. This work aimed to provide an overview of the sample preparation methods used to quantify these metal(loid)s. Therefore, a literature search was conducted in September 2024, that followed the PRISMA guidelines. Among the 48 articles selected, a wide variability in sample preparation was observed, specifically variations in aerosol generation characteristics and collection techniques. Despite the widespread use of methods as filters and impingers, many studies failed to validate critical steps such as aerosol recovery, blank corrections, and the extent of matrix effects. In addition, poor inorganic methodological practices were often applied, such as excessive use of glass materials for aerosol collection or other sample preparation steps. Therefore, further standardization of methodologies is urgently needed to improve the reliability of metal quantification in e-cigarette aerosols, which could potentially enhance regulatory frameworks and facilitate the routine analysis of e-cigarette emissions.

Harmful and Potentially Harmful Constituents in E-Liquids and Aerosols from Electronic Nicotine Delivery Systems (ENDS)

In 2012, the U.S. Food & Drug Administration (FDA) published an established list of 93 harmful and potentially harmful constituents (HPHCs) targeting four tobacco product types (cigarettes, cigarette tobacco, roll-your-own tobacco, smokeless tobacco). In 2016, the FDA finalized the deeming rule to regulate electronic nicotine delivery systems (ENDS). However, knowledge gaps exist regarding whether certain HPHCs are present in ENDS e-liquids and aerosols. We identified and addressed these gaps by conducting literature searches and then experimentally quantifying HPHCs in the e-liquid and aerosol of 37 ENDS brands based on gaps in the literature. The literature searches identified 66 e-liquid HPHCs and 68 aerosol HPHCs that have limited to no information regarding the quantifiability of these constituents. A contracted ISO 17025 accredited laboratory performed the HPHC quantifications. The availability of validated analytical methods in the contracted laboratory determined the HPHCs included in the study scope (63/66 for e-liquids, 64/68 for aerosols). Combining the results from the quantifications and literature searches, 36 (39%) and 34 (37%) HPHCs were found quantifiable (≥limit of quantification [LOQ]) in ENDS e-liquids and aerosols, respectively, with 25 HPHCs being quantifiable in both matrices. Quantifiability results imply potential HPHC transfers between matrices, leaching from components, or formations from aerosol generation. The study results can inform the scientific basis for manufacturers and regulators regarding regulatory requirements for HPHC reporting. The HPHC quantities can also inform evaluations of the public health impact of ENDS and public communications regarding ENDS health risks.

Understanding the Cardiovascular Fallout of E-cigarettes: A Comprehensive Review of the Literature

E-cigarettes (ECs) deliver chemicals, including nicotine. They can cause respiratory distress, addiction, cardiovascular effects, and death. More research is needed, especially regarding their impact on the cardiovascular system (CVS) and during pregnancy. Our article aims to fill this gap by summarizing studies elaborating upon the current impact of ECs and the components thereof on the CVS. Acute respiratory distress outbreaks, nicotine addiction, CVS effects, and deaths have been occasionally reported within this cohort, although these events are not uncommon with neighboring age groups. Randomized control trials implying ECs have some contribution toward quitting smoking have been studied. To regulate EC distribution, the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) have created key checkpoints. Additionally, taxation, pricing, age restriction, and media campaigns could be modulated to significantly reduce illicit sales. Education to the users, distributors, and regulators about this product can also play an aiding role in promoting responsible EC use. Another strategy about licensing could be employed, which could incentivize genuine resellers. The effects on CVS and child-bearing by ECs are grim, which calls for strict regulation, awareness, and avoidance by the teetotaler public. They may help individuals stop smoking but not without harming themselves. Strict regulations are necessary to prevent non-judicious use of these devices.